122 related articles for article (PubMed ID: 8726637)
1. The effect of 1,24(R)(OH)2D3 cream and ointment on epidermal proliferation and differentiation in mice.
Sato H; Sugimoto I; Fukuoka M; Ohta T; Kiyoki M
Dermatology; 1996; 192(3):233-8. PubMed ID: 8726637
[TBL] [Abstract][Full Text] [Related]
2. Tacalcitol (1,24(OH)2D3, TV-02) inhibits phorbol ester-induced epidermal proliferation and cutaneous inflammation, and induces epidermal differentiation in mice.
Sato H; Sugimoto I; Matsunaga T; Tsuchimoto M; Ohta T; Uno H; Kiyoki M
Arch Dermatol Res; 1996 Oct; 288(11):656-63. PubMed ID: 8931867
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profiles of high-concentration (20 microg/g) tacalcitol ointment: effects on cutaneous inflammation, epidermal proliferation, and differentiation in mice.
Sato H; Ogino Y; Takagi H; Hata J; Asano S; Ohta T; Komoriya K
J Dermatol; 2003 Jul; 30(7):510-24. PubMed ID: 12928540
[TBL] [Abstract][Full Text] [Related]
4. Topical vitamin D3 derivatives impair the epidermal permeability barrier in normal mouse skin.
von Brenken S; Jensen JM; Fartasch M; Proksch E
Dermatology; 1997; 194(2):151-6. PubMed ID: 9094464
[TBL] [Abstract][Full Text] [Related]
5. Influence of tacalcitol on cell cycle kinetics of human keratinocytes following standardized injury.
Mommers JM; ter Meulen AC; van Erp PE; van de Kerkhof PC
Skin Pharmacol Appl Skin Physiol; 1999; 12(4):174-81. PubMed ID: 10420137
[TBL] [Abstract][Full Text] [Related]
6. Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.
Kawaguchi M; Mitsuhashi Y; Kondo S
J Dermatol; 2003 Nov; 30(11):801-4. PubMed ID: 14684937
[TBL] [Abstract][Full Text] [Related]
7. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation.
Takahashi H; Ibe M; Kinouchi M; Ishida-Yamamoto A; Hashimoto Y; Iizuka H
J Dermatol Sci; 2003 Feb; 31(1):21-8. PubMed ID: 12615360
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of high-concentration (20 microg/g) tacalcitol ointment in psoriasis vulgaris.
Miyachi Y; Ohkawara A; Ohkido M; Harada S; Tamaki K; Nakagawa H; Hori Y; Nishiyama S
Eur J Dermatol; 2002; 12(5):463-8. PubMed ID: 12370136
[TBL] [Abstract][Full Text] [Related]
9. The separate daily application of tacalcitol 4 µg/g ointment and budesonide 0.25 mg/g cream is more effective than the single daily application of a two compound ointment containing calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g.
Calzavara-Pinton P; Rossi MT; Sala R; Venturini M
G Ital Dermatol Venereol; 2011 Aug; 146(4):295-9. PubMed ID: 21785396
[TBL] [Abstract][Full Text] [Related]
10. Open trial of topical tacalcitol [1 alpha 24(OH)2D3] and solar irradiation for vitiligo vulgaris: upregulation of c-Kit mRNA by cultured melanocytes.
Katayama I; Ashida M; Maeda A; Eishi K; Murota H; Bae SJ
Eur J Dermatol; 2003; 13(4):372-6. PubMed ID: 12948918
[TBL] [Abstract][Full Text] [Related]
11. The effect of tacalcitol (1,24(OH)2D3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo-controlled, double-blind study.
Gerritsen MJ; Boezeman JB; van Vlijmen-Willems IM; Van de Kerkhof PC
Br J Dermatol; 1994 Jul; 131(1):57-63. PubMed ID: 7519032
[TBL] [Abstract][Full Text] [Related]
12. Profile of clinical efficacy and safety of topical tacalcitol.
Leone G; Pacifico A
Acta Biomed; 2005 Apr; 76(1):13-9. PubMed ID: 16116820
[TBL] [Abstract][Full Text] [Related]
13. Topical treatment of psoriatic plaques with 1 alpha, 24 dihydroxyvitamin D3: a multiparameter flow cytometrical analysis of epidermal growth, differentiation and inflammation.
Glade CP; van Erp PE; van Hooijdonk CA; Elbers ME; van de Kerkhof PC
Acta Derm Venereol; 1995 Sep; 75(5):381-5. PubMed ID: 8615058
[TBL] [Abstract][Full Text] [Related]
14. Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and safety.
Van de Kerkhof PC; Werfel T; Haustein UF; Luger T; Czarnetzki BM; Niemann R; Plänitz-Stenzel V
Br J Dermatol; 1996 Nov; 135(5):758-65. PubMed ID: 8977677
[TBL] [Abstract][Full Text] [Related]
15. Proliferation is the main epidermal target in the treatment of psoriatic plaques with once daily application of tacalcitol ointment.
Castelijns FA; Gerritsen MJ; van Vlijmen-Willems IM; van Erp PJ; van de Kerkhof PC
Acta Derm Venereol; 1999 Mar; 79(2):111-4. PubMed ID: 10228627
[TBL] [Abstract][Full Text] [Related]
16. Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1a-24 (R)-dihydroxycholecalciferol (tacalcitol) cream.
Nakayama J
Eur J Dermatol; 2000; 10(7):528-32. PubMed ID: 11056423
[TBL] [Abstract][Full Text] [Related]
17. Topical tacalcitol treatment for psoriasis.
Harrison PV
Hosp Med; 2000 Jun; 61(6):402-5. PubMed ID: 10962655
[TBL] [Abstract][Full Text] [Related]
18. The potential of the essential fatty acid-deficient hairless rat as a psoriasis screening model for topical anti-proliferative drugs.
Jensen M; Groth L; Hølmer G; Hansen HS; Fullerton A
Skin Pharmacol Appl Skin Physiol; 2002; 15(6):401-13. PubMed ID: 12476014
[TBL] [Abstract][Full Text] [Related]
19. In vivo microautoradiography of [3H]1,24(OH)2D3 (tacalcitol) following topical application to normal rats and in vitro metabolism in human keratinocytes.
Ohta T; Okabe K; Azuma Y; Kiyoki M
Arch Dermatol Res; 1996 Apr; 288(4):188-96. PubMed ID: 8967791
[TBL] [Abstract][Full Text] [Related]
20. The effect of long-term treatment with tacalcitol on the psoriatic epidermis. A flow cytometric analysis.
Mommers JM; Castelijns FA; Seegers BA; Van Rossum MM; Van Hooijdonk CA; Van Erp PE; Van De Kerkhof PC
Br J Dermatol; 1998 Sep; 139(3):468-71. PubMed ID: 9767292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
